BBNX Key Statistics, Chart & Performance
The current stock price of BBNX is 18.5 USD. In the past month the price decreased by -36.62%.
BBNX Technical Analysis
BBNX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BBNX. BBNX has a great financial health rating, but its profitability evaluates not so good.
BBNX Financial Highlights
Over the last trailing twelve months BBNX reported a non-GAAP Earnings per Share(EPS) of -4.37. The EPS decreased by -24.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.59% | ||
| ROE | -26.41% | ||
| Debt/Equity | 0 |
BBNX Forecast & Estimates
16 analysts have analysed BBNX and the average price target is 33.25 USD. This implies a price increase of 79.74% is expected in the next year compared to the current price of 18.5.
For the next year, analysts expect an EPS growth of 5.2% and a revenue growth 50.79% for BBNX
BBNX Ownership
BBNX Latest News, Press Relases and Analysis
BBNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.4 | 211.72B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.14 | 189.66B | ||
| SYK | STRYKER CORP | 27.62 | 139.12B | ||
| BSX | BOSTON SCIENTIFIC CORP | 29.85 | 130.56B | ||
| BDX | BECTON DICKINSON AND CO | 14.36 | 59.11B | ||
| IDXX | IDEXX LABORATORIES INC | 56.73 | 57.12B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.82 | 48.95B | ||
| RMD | RESMED INC | 26.02 | 37.60B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.81 | 37.24B | ||
| DXCM | DEXCOM INC | 37.39 | 27.12B | ||
| PODD | INSULET CORP | 62.95 | 20.24B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.79 | 17.30B |
Related stock screener links
About BBNX
Company Profile
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 404 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
Company Info
BETA BIONICS INC
11 Hughes
Irvine CALIFORNIA US
Employees: 404
Phone: 19494277785
BETA BIONICS INC / BBNX FAQ
What does BBNX do?
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 404 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
What is the stock price of BETA BIONICS INC today?
The current stock price of BBNX is 18.5 USD. The price increased by 3.99% in the last trading session.
Does BBNX stock pay dividends?
BBNX does not pay a dividend.
What is the ChartMill rating of BETA BIONICS INC stock?
BBNX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about BETA BIONICS INC (BBNX) stock?
16 analysts have analysed BBNX and the average price target is 33.25 USD. This implies a price increase of 79.74% is expected in the next year compared to the current price of 18.5.
Is BETA BIONICS INC (BBNX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BBNX.